QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mira-pharma-initiates-multiple-ascending-dose-portion-of-ongoing-phase-1-clinical-trial-evaluating-lead-oral-candidate-ketamir-2-in-healthy-volunteers

Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potenti...

 mira-pharmaceuticals-initiates-the-multiple-ascending-dose-portion-of-its-ongoing-phase-1-clinical-trial-evaluating-its-lead-oral-candidate-ketamir-2-in-healthy-volunteers-advancing-toward-phase-2a-clinical-evaluation-in-chemotherapy-related-pain-a-condition-with-no-approved-treatments-and-potential-for-fda-fast-track-consideration

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company") announced that it has initiated the multiple...

 mira-pharmaceuticals-sells-1751000-shares-at-219-each

-SEC Filing

 mira-pharmaceuticals-stock-surges-following-positive-preclinical-data

MIRA Pharmaceuticals shares are trading significantly higher on Thursday following the announcement of new preclinical data for...

Core News & Articles

TSM: 2% | Taiwan Semiconductor Lifts Outlook After Blowout Quarter, CEO Says AI Signals From Clients Are 'Very Strong' ...

 why-mira-pharmaceuticals-shares-rose-69-after-hours

Mira Pharmaceuticals shares surged 68.94% in after-hours trading after the company reported promising preclinical results for ...

 mira-pharmaceuticals-reports-new-preclinical-data-showing-that-oral-administration-of-mira-55-normalized-pain-and-significantly-reduced-inflammation-outperforming-injected-morphine-in-a-chronic-inflammatory-pain-model

https://www.sec.gov/Archives/edgar/data/1904286/0001493152-25-018141-index.html

 mira-pharmaceuticals-reports-ketamir-2-restored-normal-behavior-in-ptsd-animal-study-expands-focus-beyond-pain

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company dev...

 mira-pharmaceuticals-announces-ketamir-2-reverses-ptsd-like-symptoms-in-animal-study-supporting-ongoing-clinical-development

MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals MIRA P...

 mira-pharmaceuticals-announces-ptsd-data-for-ketamir-2

-Sec Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION